semaglutide for autoimmune and Diseases (Ozempic and Wegovy) Is semaglutide causing your symptoms?

Follow the dosage directions and usage instructions provided accordingly

MASH (Stage F2-F3) (Wegovy): SUBQ: 2.4mg weekly

A 2023 analysis published in JAMA Network Open found that high out-of-pocket costs for GLP-1 receptor agonists were the primary driver of treatment discontinuation within the first 12 months, with 42.1% of commercially insured patients stopping therapy by month 12

However, it has been reported that the use of aromatase inhibitors resulted in reduced hot flushes as compared to GnRH agonist, while the adverse effect of aromatase inhibitors are usually mild and occurs more frequently with prolonged use